Table 1.
Immune-mediated disorder clinical trials using mesenchymal stem/stromal cell (MSC) therapy.
| Immune-Mediated Disorders | Number of Clinical Trials | Year of First Clinical Trial | References |
|---|---|---|---|
| Graft vs. host disease | 49 | 2004 | [24] |
| Inflammatory bowel disease | 23 | 2006 | [25] |
| Multiple sclerosis | 29 | 2006 | [26] |
| Systemic lupus erythematosus | 10 | 2007 | [27,28] |
| Type I diabetes | 26 | 2008 | [29,30,31] |
| Primary Sjögren syndrome | 1 | 2009 | [33] |
| Type II diabetes | 13 | 2010 | [32] |
| Autoimmune hepatitis | 2 | 2011 | NCT01661842 and NCT02997878 |
| Ankylosing spondylitis | 2 | 2011 | [34] |
| Chronic urticaria | 1 | 2017 | NCT02824393 |
| Refractory autoimmune thrombocytopenia | 1 | 2019 | NCT04014166 |